¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Oncogene Fusion"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • signaling oncogene
    ½ÅÈ£Á¾¾çÀ¯ÀüÀÚ
  • atrial fusion beat
    ½É¹æÀ¶ÇÕ¹Úµ¿
  • binocular fusion
    µÎ´«À¶ÇÕ, ¾ç¾ÈÀ¶ÇÕ
  • critical flicker fusion
    ÀÓ°èÇø®Ä¿À¶ÇÕ
  • critical fusion frequency
    ÀÓ°èÀ¶ÇÕºóµµ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • extraarticular fusion
    °üÀý¿Ü°íÁ¤(¼ú)
  • epiphyseal fusion
    »À³¡À¯ÇÕ(¼ú), °ñ´ÜÀ¯ÇÕ(¼ú)
  • fusion
    1. À¶ÇÕ, À¶ÇØ 2. °íÁ¤¼ú, À¯ÇÕ¼ú
  • fusion beat
    À¶ÇÕ¹Úµ¿
  • fusion defect
    À¶ÇÕ°áÇÔ
  • spinal fusion
    ôÃßÀ¯ÇÕ(¼ú)
  • sensory fusion
    °¨°¢À¶ÇÕ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fusion
    1.À¶ÇÕ, À¶ÇØ, 2.°íÁ¤¼ú, À¯ÇÕ¼ú
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ, Á¾¾ç¿ø
  • signaling oncogene
    ½ÅÈ£Á¾¾çÀ¯ÀüÀÚ
  • fusion angle
    À¶ÇÕ°¢
  • binocular fusion
    µÎ´«À¶ÇÕ, ¾ç¾ÈÀ¶ÇÕ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • critical flicker fusion
    ÀÓ°èÇø®Ä¿À¶ÇÕ
  • critical fusion frequency
    ÀÓ°èÀ¶ÇÕºóµµ
  • fusion defect
    À¶ÇÕ°áÇÔ
  • epiphyseal fusion
    »À³¡À¯ÇÕ¼ú, °ñ´ÜÀ¯ÇÕ¼ú
  • extraarticular fusion
    °üÀý¿Ü°íÁ¤¼ú
  • fusion
    À¶ÇÕ, À¶ÇØ, °íÁ¤¼ú, À¯ÇÕ¼ú
  • sensory fusion
    °¨°¢À¶ÇÕ
  • spinal fusion
    ôÃß°íÁ¤¼ú, ôÃßÀ¯ÇÕ¼ú
  • urethrohymenal fusion
    ¿äµµÃ³³à¸·À¶ÇÕ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Erb-A oncogene
    Erb-A ¾ÏÀ¯ÀüÀÚ
  • Erb-B oncogene
    Erb-B ¾ÏÀ¯ÀüÀÚ
  • Fins oncogene
    Fins ¾ÏÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÁ¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÇü¾ÏÀ¯ÀüÀÚ, ¿øÇü¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿ø¹ß¾ÏÀ¯ÀüÀÚ(ê«Û¡äßëºîîí­)
  • Pannums fusion area
    ÆÄ´®À¶ÇÕ¿ª
  • abnormal fusion
    ºñÁ¤»óÀ¶ÇÕ
  • fusion
    À¶ÇÕ(ë×ùê)
  • fusion
    À¶ÇÕÁõ
  • fusion
    À¶ÇÕ
  • fusion activity
    À¶ÇÕ´É
  • fusion angle
    À¶ÇÕ°¢
  • fusion defect
    À¶ÇÕ°áÇÔ
  • fusion defect (cleft palate)
    À¶ÇÕ°áÇÔ (ÀÔõÀå°¥¸²Áõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷¾ÏÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ(ðþåËë¶îîí­), Á¾¾ç¿ø(ðþåË¿ø)
  • proto-oncogene
    ¿øÇü¾ÏÀ¯ÀüÀÚ, ¿øÇü¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÁ¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿ø¹ß¾ÏÀ¯ÀüÀÚ(ê«Û¡äßëºîîí­)
  • trk proto-oncogene
    trk¿øÇüÁ¾¾çÀ¯ÀüÀÚ
  • abnormal fusion
    ºñÁ¤»óÀ¶ÇÕ
  • binocular fusion
    ¾ç¾ÈÀ¶ÇÕ(¡­ë×ùê).
  • carpal fusion
    ¼Õ¸ñ»ÀÀ¶ÇÕÁõ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(¡­ë×ùê)
  • cell fusion
    ¼¼Æ÷À¶ÇÕ (¡­ë×ùê)
  • central fusion
    Áß½ÉÀ¶ÇÕ
  • color fusion
    »öÀ¶ÇÕ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fusion defect
    À¶ÇÕ°áÇÔ
    [¿¾ ¿ë¾î] À¶ÇÕ°áÇÔ
  • Fusion defect (Cleft palate)
    À¶ÇÕ°áÇÔ (ÀÔõÀå°¥¸²Áõ)
    [¿¾ ¿ë¾î] À¶ÇÕ°áÇÔ (ÀÔõÀå°¥¸²Áõ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷ ¾ÏÀ¯ÀüÀÚ(á¬øàäßë¶îîí­)
  • oncogene
    ¾ÏÀ¯ÀüÀÚ(äßë¶îîí­)
  • oncogene theory
    ¾ÏÀ¯ÀüÀÚÀÌ·Ð(äßë¶îîí­ìµÖå)
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
  • fusion
    À¶ÇÕ(ë×ùê)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • gene fusion
    À¯ÀüÀÚ À¶ÇÕ(ë¶îîí­ë×ùê)
  • nuclear fusion
    ÇÙÀ¶ÇÕ(ú·ë×ùê)
  • plasmid fusion
    Çö󽺹̵å À¶ÇÕ(ë×ùê)
  • replicon fusion
    ·¹Çø®ÄÜ À¶ÇÕ(ë×ùê)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fusion
    À¶ÇÕ, À¯ÇÕ, °íÁ¤¼ú
  • fusion
    À¶ÇÕ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CFF critical flicker fusion [test]; critical fusion frequency; cystic fibrosis factor; Cystic Fibrosis F...
cff critical flicker fusion; critical fusion frequency
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
AXL anexelekto [oncogene]; axillary lymphoscintigraphy
c-onc cellular oncogene
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
c-onc cellular oncogene
GRO-alpha Growth Regulated Oncogene-alpha
GROalpha Growth-related oncogene-alpha
ALIF Anterior lumbar interbody fusion
CFF Critical Flicker Fusion
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cellular oncogene
    ¼¼Æ÷ ¾Ï À¯ÀüÀÚ
    ¼¼Æ÷ÀÇ ¿øÀο¡ ÀÇÇØ¼­ Á¾¾çÇü¼ºÀ» ÀÏÀ¸Å°´Â À¯ÀüÀÚ.
  • abnormal fusion
    ºñÁ¤»ó À¶ÇÕ
    ¹ß»ý ½Ã Á¶Á÷ÀÌ Á¤»óÀûÀ¸·Î ÇÕÃÄÁöÁö ¸øÇÏ´Â »óÅÂ. ´ëºÎºÐ Á¤Áߺο¡ °á¼ÕÀ» ³ªÅ¸³½´Ù.
  • binocular fusion
    ¾ç ¾È À¶ÇÕ
  • cell fusion
    ¼¼Æ÷ ÀÀÇÕ, ¼¼Æ÷ À¶ÇÕ
    µÎ Á¾·ù ÀÌ»óÀÇ ¼¼Æ÷¸¦ ¹ÙÀÌ·¯½º,
  • cervical fusion syndrome
    °æºÎ À¯ÇÕ ÁõÈıº
  • critical flicker fusion frequency
    ÇѰè ÇÁ¸¯Ä¿ À¶ÇÕÄ¡, ÇѰè ÇÁ¸¯Ä¿ Ä¡
  • flicker fusion test
    ÇÁ¸¯Ä¿ À¶ÇÕ °Ë»ç
  • fusion
    À¶ÇÕ, À¶ÇØ, À¯ÇÕ, À¶»ó, °íÁ¤¼ú
  • fusion teeth
    À¯ÇÕÄ¡
  • imperfect fusion
    ºÒ¿ÏÀü À¯ÇÕ
  • latent heat of fusion
    À¶ÇØ Àá¿­
    ¹°ÁúÀÌ ³ì´Â °úÁ¤¿¡¼­ ¿ÂµµÀÇ º¯È­¸¦ ¼ö¹ÝÇÏÁö ¾Ê°í Èí¼ö ¶Ç´Â ¹æÃâµÇ´Â ¿­·®.
  • motor fusion
    ¿îµ¿ À¶ÇÕ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
oncogene proteins, fusion The translation products of the fusion between an oncogene and another gene. The latter may be of viral or cellular origin.
(12 Dec 1998)
recessive oncogene <molecular biology> A single copy of this gene issufficient to suppress cell proliferation, the loss of both copies of the gene contributes to cancer formation.
(09 Oct 1997)
viral oncogene <molecular biology> A viral gene that contributes to cancer development in vertebrate hosts.
(09 Oct 1997)
cellular oncogene <molecular biology> A normal gene that, when mutated or improperly expressed, can cause cancer to develop.
(09 Oct 1997)
c-oncogene <molecular biology> A normal gene which has a tumour-producing insert that may have originated from a virus in it, turning it into a proto-oncogene.
When these genes are sufficiently mutated, amplified, or over-expressed (transcribed too many times), they can begin to produce cancers.
(05 Jan 1998)
proto-oncogene <molecular biology> The normal, cellular equivalent of an oncogene, thus usually a gene involved in the signalling or regulation of cell growth. In general, cellular proto-oncogenes are prefixed with a c, rather than their abnormal viral counterparts, that are prefixed with a v, for example c myc and v myc.
They are fragments of DNA, related to oncogenes but are the normal switches used to control growth and tissue repair.
(06 Oct 1997)
proto-oncogene protein p21(ras) Cellular protein encoded by the c-ras genes. The protein has GTPase activity and is involved in transmembrane signal transduction as a guanine nucleotide binding protein. Elevated levels of p21 c-ras have been associated with neoplasia.
(12 Dec 1998)
proto-oncogene protein pp60(c-src) <enzyme> Membrane-associated tyrosine-specific kinase encoded by the c-src genes. It has an important role in cellular growth control. Truncation of carboxy-terminal residues in pp60(c-src) leads to pp60(v-src) which has the ability to transform cells. This kinase pp60 c-src should not be confused with csk, also known as c-src kinase.
Registry number: EC 2.7.1.-
(12 Dec 1998)
proto-oncogene proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
(12 Dec 1998)
proto-oncogene proteins c-abl Membrane proteins encoded by the c-abl genes. They exhibit tyrosine kinase activity and play a role in normal haematopoiesis especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific n-terminal amino acids are deleted, releasing the kinase from negative regulation.
(12 Dec 1998)
proto-oncogene proteins c-bcl-2 Membrane proteins encoded by the bcl-2 genes and serving as a potent inhibitor of cell death by apoptosis. The proteins are found on mitochondrial, microsomal, and nuclear membrane sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
(12 Dec 1998)
proto-oncogene proteins c-erbb-2 Cellular proteins in the epidermal growth factor receptor family encoded by the c-erbb genes. These proteins are overexpressed in a significant portion of adenocarcinomas found at various sites, especially in the breast. Gene amplification appears to be the predominant method leading to overexpression.
(12 Dec 1998)
proto-oncogene proteins c-fos Cellular DNA-binding proteins encoded by the c-fos genes (genes, fos). They are involved in growth-related transcriptional control. C-fos combines with c-jun (proto-oncogene proteins c-jun) to form a c-fos/c-jun heterodimer (transcription factor ap-1) that binds to the tre (tpa-responsive element) in promoters of certain genes.
(12 Dec 1998)
proto-oncogene proteins c-jun Cellular DNA-binding proteins encoded by the c-jun genes (genes, jun). They are involved in growth-related transcriptional control. There appear to be three distinct functions: dimerization (with c-fos), DNA-binding, and transcriptional activation. Oncogenic transformation can take place by constitutive expression of c-jun.
(12 Dec 1998)
proto-oncogene proteins c-kit Tyrosine kinase membrane receptors which are the natural ligands for mast cell growth factor (steel factor). This interaction is crucial for the development of haematopoietic, gonadal, and pigment stem cells.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Oncogene Fusion - »õâ The GENETIC RECOMBINATION of the parts of two or more GENES, including an ONCOGENE as at least one of the fusion partners. Such gene fusions are often detected in neoplastic cells and are transcribed into ONCOGENE FUSION PROTEINS.
    Synonyms : Oncogene Fusions
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oncogene
    ¹ß¾ÏÀ¯ÀüÀÚ
  • fusion
    ¿ëÇØ; À¶ÇØ
  • atomic fusion
    ¿øÀÚÇÙ À¶ÇÕ
  • atonic fusion
    ¿øÀÚÇÙÀ¶ÇÕ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • fusion
    À¶ÇØ;À¶Çع°;(Á¤´çÀÇ)ÇÕµ¿
  • fusion bomb
    ¼ö¼ÒÆøÅº
  • fusion point
    À¶Á¡;¿ëÇØÁ¡
  • fusion reaction
    ÇÙÀ¶ÇÕ ¹ÝÀÀ
  • fusion reactor
    ÇÙÀ¶ÇÕ·Î
  • nuclear fusion
    ÇÙÀ¶ÇÕ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á